Stay updated with breaking news from Factor Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, announced its...
SAN DIEGO, April 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on...
Exacis CEO Gregory Fiore, MD, commented, “We welcome CCRM as a key partner to allow us to rapidly advance our virus-free manufacturing...
Author Bio Eric has been writing about stocks and finance since the mid-1990s, when he lived in Prague, Czech Republic. Over the course of a varied career, he has also been a radio newscaster, an investment banker, and a bass player in a selection of rock and roll bands. A native New Yorker, he currently lives in Los Angeles. What happened Shares of Brooklyn ImmunoTherapeutics (NYSEMKT:BTX), no stranger to sharp stock price movements lately, zoomed more than 6% higher on Monday. The catalyst was an acquisition announced that morning by the clincial-stage biotech compa...
Share this article Share this article CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Exacis Biotherapeutics Inc., a development-stage immuno-oncology company working to democratize access to the most advanced and effective cancer treatments, revealed key data related to its engineered iPSC-derived NK-cell platform at the American Society of Gene & Cell Therapy 24th Annual Meeting. These data include the successful generation of functional NK cells from iPSCs engineered to contain a biallelic knockout of a key MHC class I gene. Exacis' cell engineering strategy is designed to allow its E...